Key Takeaways From Gilead Sciences Analyst Ratings
Portfolio Pulse from Benzinga Insights
Analysts' ratings for Gilead Sciences (NASDAQ:GILD) over the last quarter show a mix of sentiments, with most analysts being indifferent. The average 12-month price target has decreased from $82.22 to $79.0. Recent actions by analysts include maintaining, lowering, and announcing ratings, reflecting their reactions to Gilead's market performance and financial indicators.
July 01, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analysts' ratings for Gilead Sciences show mixed sentiments, with most analysts being indifferent. The average 12-month price target has decreased from $82.22 to $79.0, indicating a slight bearish outlook. Recent actions by analysts include maintaining, lowering, and announcing ratings, reflecting their reactions to Gilead's market performance and financial indicators.
The decrease in the average 12-month price target and the mixed sentiments from analysts suggest a slightly bearish outlook for Gilead Sciences in the short term. The majority of analysts are indifferent, with some lowering their price targets, indicating concerns about the company's market performance and financial indicators.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100